"Network pharmacology: systematic drug discovery"
| e-Therapeutics clinical development pipeline |
 |
 |
|
ETS2101 is a drug that promotes apoptosis (programmed death) of malignant cancer cells. It is supported by preclinical data in multiple cancer types and a substantial safety file from its previous development as a potential treatment for trauma patients. We plan to start a phase I programme during Q1 2012. This will comprise two trials: a dose-escalating study that will enrol patients with a variety of solid tumours; and a focused investigator-initiated trial in patients with primary or secondary tumours in the brain. Together, these trials will allow the Company to probe the broad range of cancers where ETS2101 could provide benefit while also pursuing a specific indication where preclinical data were especially promising. Initial data from the phase I programme should be available in 2012 and we expect final results from both trials in 2013. The Company will conduct additional non-clinical work in parallel with the trials in order to allow rapid progress to phase II if data are positive. ETX1153c is a drug with high potency against C. difficile, a bacterium that is responsible for severe and sometimes life-threatening outbreaks of diarrhoea in hospitalised patients. ETX1153c has shown activity that extends to resistant strains in laboratory testing. We expect to initiate phase I development in Q2 2012 and to complete this phase by the end of the year. Provided phase I data are satisfactory, we intend to complete a phase II trial during 2013. ETS6103 is a drug we are developing for major depressive disorder. The drug has already produced encouraging data in a small phase II study in which it was compared with the tricyclic antidepressant amitriptyline. Our next step is to conduct a phase IIb trial, which will evaluate a range of dosing options. We plan to start this trial in Q3 2012 and to complete it in the second half of 2013.
|
Latest News
Dr Daniel Elger will present an overview of the Company's strategy, platform and clinical development programmes at the 14th Annual BIO CEO & Investor Conference in New York on Monday 13 February at 2.00 pm EST (1900 BST). Click here for the webcast of the presentation.
|
e-Therapeutics PLC
Holland Park,
Holland Drive,
Newcastle upon Tyne,
NE2 4LZ
| Terms & ConditionsPrivacy PolicyCareersSitemapContent Management Website Newcastle |
|
|
|
